Osteosarcoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Osteosarcoma is the most commonly diagnosed primary malignancy of bone, particularly among children and adolescents. Nonetheless, it is rare, representing less than 1% of all cancers diagnosed in the United States, and there is a paucity of population-based, comprehensive data on its occurrence and outcome. In young patients, it often arises in the metaphyses of long bones, such as the distal femur, proximal tibia, and proximal humerus. Although most osteosarcoma cases occur in adolescence, there is a second incidence peak in the elderly (seventh and eighth decades). Osteosarcomas in elderly patients often are considered secondary neoplasms attributed to the sarcomatous transformation of Paget's disease of bone or some other benign bone lesion. In elderly patients, tumors occur more commonly in axial locations and areas previously irradiated or with underlying bone abnormalities.
- The incidence rates vary depending on age, race, sex and several other factors. The rates vary worldwide from 3-5 per million in males to 2-4 per million in females.
- In general, it is around 5.2 for children aged 0-19 years per year per million people. It is ranked the eighth highest childhood cancer at around 2.4% of tumors diagnosed.
Thelansis’s “Osteosarcoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Osteosarcoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Osteosarcoma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Osteosarcoma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment